繁體
  • 简体中文
  • 繁體中文
×

熱門資訊> 正文

葛兰素史克公布第二季度业绩，修改前景

2025-07-30 17:04

  • GSK press release (NYSE:GSK): Q2 Non-GAAP EPS of 46.50p
  • Revenue of £7.99B (+1.1% Y/Y)
  • Specialty Medicines sales £3.3 billion (+15%); Respiratory, Immunology & Inflammation £1.0 billion (+10%); Oncology £0.5 billion (+42%); HIV sales £1.9 billion (+12%)
  • Vaccines sales £2.1 billion (+9%); Shingrix £0.9 billion (+6%); Meningitis vaccines £0.4 billion (+22%); and Arexvy £0.1 billion (+13%)
  • General Medicines sales £2.6 billion (-6%); Trelegy £0.8 billion (+4%)
  • Total operating profit +33% and Total EPS +35% driven by lower CCL charges partly offset by intangible asset impairments
  • Core operating profit +12% and Core EPS +15% reflecting Specialty Medicines and Vaccines growth, higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines.
  • GSK revises its full-year 2025 guidance at constant exchange rates (CER). GSK expects its turnover to increase towards the top end of the range between 3% to 5% and Core operating profit to increase towards the top end of the range between 6% to 8%. Core earnings per share is expected to increase towards the top end of the range between 6% to 8%. The Core earnings per share guidance includes the implementation of the £2 billion share buyback programme to the end of Q2 2026.
  • The Group has made planning assumptions that we expect turnover for Specialty Medicines to increase at a low teens percentage, Vaccines to decrease by a low-single digit per cent to broadly stable, and General Medicines to be broadly stable.

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
（工作日09：30 - 次日05：30）
客戶端：
關注我們：
  • 微信公眾號二維碼

© 2025 深圳市時代華盛網絡科技有限公司版權所有 粵ICP備16068286號